You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 百濟神州(6160.HK)高開3.69% 與諾華製藥簽訂合作協議 將獲3億美元首付款
格隆匯 12-21 09:31
格隆匯12月21日丨百濟神州(6160.HK)高開3.69%,報162.9港元,總市值2168億港元。百濟神州公佈,近日,公司全資子公司 BeiGene Switzerland GmbH (百濟瑞士)與 Novartis Pharma AG(諾華製藥)簽訂一份《選擇權、合作和許可協議》。根據《合作協議》,公司向諾華製藥授予一項獨家的、基於時間的選擇權,以使諾華製藥可以通過行使該選擇權獲得在美國等國對公司的在研TIGIT抑制劑ociperlimab進行開發、生產和商業化的獨家許可。根據《合作協議》,諾華製藥將向公司支付3億美元的首付款。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account